ArticleAnnals of hematology2026
Reduced number of endothelial progenitor cells in adult patients with beta thalassemia major.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Beta-thalassemia major (TM) is associated with a high incidence of thromboembolic events and prothrombotic changes, suggesting a chronic hypercoagulable state. Hematopoietic derived endothelial progenitor cells (hEPCs), derived from the bone marrow, contribute to vascular repair, and their quantity and function inversely correlate with thrombotic risk. In this study, we aimed to evaluate the number and colony-forming capacity of hEPCs in adult patients with TM. hEPCs were isolated from peripheral blood mononuclear cells of TM patients and healthy controls. Flow cytometry was used to measure the proportion of mononuclear cells co-expressing VEGFR-2 and CD34 or CD133. hEPCs were cultured for 7 days, after which colony-forming capacity and viability were assessed via microscopy and MTT assay. TM patients (n = 25) had a significantly lower proportion of VEGFR-2+CD34+ cells compared to controls (n = 11); 0.95% (0.36–1.65%) vs. 1.78% (1.1–4.2%), p = 0.02. hEPC colony counts and viability were also reduced: 0 (0–0.5) vs. 3 (2–4), and 0.02AU (0.01–0.05) vs. 0.2AU (0.18–0.23), respectively (both p < 0.0001). Subgroup analyses suggested lower VEGFR-2+CD34+ proportions in patients with prior thrombosis (n = 6) and in splenectomized patients (n = 21). Patients with TM exhibit reduced hEPC numbers and impaired colony-forming capacity, which may be associated with the hypercoagulable state observed in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.